The assessment and management of delirium in cancer patients

Oncologist

Volumn 14, Issue 10, 2009, Pages 1039-1049

  Bush, Shirley H ^a,b,c,d   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Southern Healthcare Network   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antipsychotic agents; Delirium; Diagnostic techniques and procedures; Neoplasms; Palliative care

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CORTICOSTEROID; FENTANYL; HALOPERIDOL; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROMORPHONE; HYPNOTIC AGENT; METHADONE; METOCLOPRAMIDE; MORPHINE; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE DERIVATIVE; OXYCODONE; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; QUETIAPINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; NARCOTIC ANALGESIC AGENT;

CANCER PATIENT; DELIRIUM; DISTRESS SYNDROME; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; NEUROPSYCHIATRY; NEUROTOXICITY; PATIENT COUNSELING; PRIORITY JOURNAL; REVIEW; CHEMICALLY INDUCED DISORDER; COUNSELING; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; NEOPLASM; OPIATE ADDICTION;

ANALGESICS, OPIOID; ANTINEOPLASTIC AGENTS; ANTIPSYCHOTIC AGENTS; COUNSELING; DELIRIUM; DEPRESSION; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEOPLASMS; OPIOID-RELATED DISORDERS;

EID: 73349122620     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0122     Document Type: Review

References (115)

1. Engel GL, Romano J. Delirium, a syndrome of cerebral insufficiency. J Chronic Dis 1959;9:260-277.
2. Bruera E, Miller L, McCallion J et al. Cognitive failure in patients with terminal cancer: A prospective study. J Pain Symptom Manage 1992;7:192-195.
3. Inouye SK. Delirium in older persons. N Engl J Med 2006;354:1157-1165.
4. Braiteh F, El Osta B, Palmer JL et al. Characteristics, findings, and outcomes of palliative care inpatient consultations at a comprehensive cancer center. J Palliat Med 2007;10:948-955.
5. Breitbart W, Bruera E, Chochinov H et al. Neuropsychiatric syndromes and psychological symptoms in patients with advanced cancer. J Pain Symptom Manage 1995;10:131-141.
6. Lawlor PG, Bruera ED. Delirium in patients with advanced cancer. Hematol Oncol Clin North Am 2002;16:701-714.
7. Lawlor PG, Gagnon B, Mancini IL et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: A prospective study. Arch Intern Med 2000;160:786-794.
8. Pereira J, Hanson J, Bruera E. The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer 1997;79:835-842.
9. Breitbart W, Gibson C, Tremblay A. The delirium experience: Delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. Psychosomatics 2002;43:183-194.
10. Morita T, Hirai K, Sakaguchi Y et al. Family-perceived distress from delirium-related symptoms of terminally ill cancer patients. Psychosomatics 2004;45:107-113.
11. Bruera E, Bush SH, Willey J et al. Impact of delirium and recall on the level of distress in patients with advanced cancer and their family caregivers. Cancer 2009;115:2004-2012.
12. Siddiqi N, House AO, Holmes JD. Occurrence and outcome of delirium in medical in-patients: A systematic literature review. Age Ageing 2006;35:350-364.
13. Pautex S, Herrmann FR, Zulian GB. Factors associated with falls in patients with cancer hospitalized for palliative care. J Palliat Med 2008;11:878-884.
14. Caraceni A, Nanni O, Maltoni M et al. Impact of delirium on the short term prognosis of advanced cancer patients. Italian Multicenter Study Group on Palliative Care. Cancer 2000;89:1145-1149.
15. Delirium due to a general medical condition. In: American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, Text Revision, Fourth Edition. Washington, DC: American Psychiatric Association, 2000:141-143.
16. Centeno C, Sanz A, Bruera E. Delirium in advanced cancer patients. Palliat Med 2004;18:184-194.
17. Massie MJ, Holland J, Glass E. Delirium in terminally ill cancer patients. Am J Psychiatry 1983;140:1048-1050.
18. Liptzin B, Levkoff SE. An empirical study of delirium subtypes. Br J Psychiatry 1992;161:843-845.
19. Meagher D, Moran M, Raju B et al. A new data-based motor subtype schema for delirium. J Neuropsychiatry Clin Neurosci 2008;20:185-193.
20. Seitz DP, Gill SS, van Zyl LT. Antipsychotics in the treatment of delirium: A systematic review. J Clin Psychiatry 2007;68:11-21.
21. Breitbart W, Tremblay A, Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics 2002;43:175-182.
22. Alici-Evcimen Y, Breitbart W. An update on the use of antipsychotics in the treatment of delirium. Palliat Support Care 2008;6:177-182.
23. Spiller JA, Keen JC. Hypoactive delirium: Assessing the extent of the problem for inpatient specialist palliative care. Palliat Med 2006;20: 17-23.
24. Lawlor P, Gagnon B, Mancini I et al. Phenomenology of delirium and its subtypes in advanced cancer patients: A prospective study [abstract]. J Palliat Care 1998;14:106.
25. Morita T, Tei Y, Tsunoda J et al. Underlying pathologies and their associations with clinical features in terminal delirium of cancer patients. J Pain Symptom Manage 2001;22:997-1006.
26. Bruera E, Fainsinger RL, Miller MJ et al. The assessment of pain intensity in patients with cognitive failure: A preliminary report. J Pain Symptom Manage 1992;7:267-270.
27. Trzepacz PT. Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Semin Clin Neuropsychiatry 2000;5:132-148.
28. Agar M, Lawlor P. Delirium in cancer patients: A focus on treatment-induced psychopathology. Curr Opin Oncol 2008;20:360-366.
29. Vella-Brincat J, Macleod AD. Adverse effects of opioids on the central nervous systems of palliative care patients. J Pain Palliat Care Pharmacother 2007;21:15-25.
30. de Rooij SE, van Munster BC, Korevaar JC et al. Cytokines and acute phase response in delirium. J Psychosom Res 2007;62:521-525.
31. Adamis D, Lunn M, Martin FC et al. Cytokines and IGF-I in delirious and non-delirious acutely ill older medical inpatients. Age Ageing 2009;38:326-332.
32. van Munster BC, Korevaar JC, Zwinderman AH et al. Time-course of cytokines during delirium in elderly patients with hip fractures. J Am Geriatr Soc 2008;56:1704-1709.
33. Gaudreau JD, Gagnon P. Psychotogenic drugs and delirium pathogenesis: The central role of the thalamus. Med Hypotheses 2005;64:471-475.
34. Ljubisavljevic V, Kelly B. Risk factors for development of delirium among oncology patients. Gen Hosp Psychiatry 2003;25:345-352.
35. Gaudreau JD, Gagnon P, Harel F et al. Psychoactive medications and risk of delirium in hospitalized cancer patients. J Clin Oncol 2005;23:6712-6718.
36. Han L, McCusker J, Cole M et al. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med 2001;161:1099-1105.
37. Bruera E, Pereira J. Neuropsychiatric toxicity of opioids. In: Jensen TS, Turner JA, Wiesenfeld-Hallin Z, eds. Proceedings of the 8th World Congress on Pain: Progress in Pain Research and Management, Volume 8. Seattle: IASP Press, 1997:717-738.
38. Mercadante S. Opioid rotation for cancer pain: Rationale and clinical aspects. Cancer 1999;86:1856-1866.
39. Leipzig RM, Goodman H, Gray G et al. Reversible, narcotic-associated mental status impairment in patients with metastatic cancer. Pharmacology 1987;35:47-54.
40. Fountain A. Visual hallucinations: A prevalence study among hospice inpatients. Palliat Med 2001;15:19-25.
41. Sjøgren P, Eriksen J. Opioid analgesics. In: Bruera E, Higginson IJ, Ripamonti C et al., eds. Textbook of Palliative Medicine. London: Hodder Arnold, 2006:380-389.
42. Gong QL, Hedner J, Björkman R et al. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain 1992;48:249-255.
43. Penson RT, Joel SP, Clark S et al. Limited phase I study of morphine-3-glucuronide. J Pharm Sci 2001;90:1810-1816.
44. Sjøgren P. Clinical implications of morphine metabolites. In: Portenoy RK, Bruera E, eds. Topics in Palliative Care, Volume 1. New York: Oxford University Press, 1997:163-175.
45. Mercadante S, Ferrera P, Villari P et al. Hyperalgesia: An emerging iatrogenic syndrome. J Pain Symptom Manage 2003;26:769-775.
46. Gupta N, de Jonghe J, Schieveld J et al. Delirium phenomenology: What can we learn from the symptoms of delirium? J Psychosom Res 2008;65:215-222.
47. Breitbart W, Chochinov HM, Passik SD. Psychiatric symptoms in palliative medicine. In: Doyle D, Hanks G, Cherny NI et al., eds. Oxford Textbook of Palliative Medicine, Third Edition. New York: Oxford University Press, 2004:746-771.
48. Macleod AD, Whitehead LE. Dysgraphia and terminal delirium. Palliat Med 1997;11:127-132.
49. Bruera E, Spachynski K, MacEachern T et al. Cognitive failure in cancer patients in clinical trials [letter]. Lancet 1993;341:247-248.
50. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
51. Bruera E, Franco JJ, Maltoni M et al. Changing pattern of agitated impaired mental status in patients with advanced cancer: Association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 1995;10:287-291.
52. Breitbart W, Marotta R, Platt MM et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996;153:231-237.
53. Hjermstad M, Loge JH, Kaasa S. Methods for assessment of cognitive failure and delirium in palliative care patients: Implications for practice and research. Palliat Med 2004;18:494-506.
54. Smith MJ, Breitbart WS, Platt MM.Acritique of instruments and methods to detect, diagnose, and rate delirium. J Pain Symptom Manage 1995;10:35-77.
55. Kean J, Ryan K. Delirium detection in clinical practice and research: Critique of current tools and suggestions for future development. J Psychosom Res 2008;65:255-259.
56. Inouye SK, van Dyck CH, Alessi CA et al. Clarifying confusion: The confusion assessment method. A new method for detection of delirium. Ann Intern Med 1990;113:941-948.
57. Breitbart W, Rosenfeld B, Roth A et al. The Memorial Delirium Assessment Scale. J Pain Symptom Manage 1997;13:128-137.
58. Lawlor PG, Nekolaichuk C, Gagnon B et al. Clinical utility, factor analysis, and further validation of the Memorial Delirium Assessment Scale in patients with advanced cancer: Assessing delirium in advanced cancer. Cancer 2000;88:2859-2867.
59. Gaudreau JD, Gagnon P, Harel F et al. Fast, systematic, and continuous delirium assessment in hospitalized patients: The nursing delirium screening scale. J Pain Symptom Manage 2005;29:368-375.
60. Gagnon P, Allard P, Mâsse B et al. Delirium in terminal cancer: A prospective study using daily screening, early diagnosis, and continuous monitoring. J Pain Symptom Manage 2000;19:412-426.
61. Ryan K, Leonard M, Guerin S et al. Validation of the confusion assessment method in the palliative care setting. Palliat Med 2009;23:40-45.
62. Fadul N, Kaur G, Zhang T et al. Evaluation of the Memorial Delirium Assessment Scale (MDAS) for the screening of delirium by means of simulated cases by palliative care health professionals. Support Care Cancer 2007;15:1271-1276.
63. Bruera E, Kuehn N, Miller MJ et al. The Edmonton Symptom Assessment System (ESAS): A simple method for the assessment of palliative care patients. J Palliat Care 1991;7:6-9.
64. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995;10:378-384.
65. Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol 2002;20:348-352.
66. Mercadante S, Bruera E. Opioid switching: A systematic and critical review. Cancer Treat Rev 2006;32:304-315.
67. Eisele JH Jr, Grigsby EJ, Dea G. Clonazepam treatment of myoclonic contractions associated with high-dose opioids: Case report. Pain 1992;49:231-232.
68. Slatkin N, Rhiner M. Treatment of opioid-induced delirium with acetylcholinesterase inhibitors: A case report. J Pain Symptom Manage 2004;27:268-273.
69. Overshott R, Karim S, Burns A. Cholinesterase inhibitors for delirium. Cochrane Database Syst Rev 2008:(1):CD005317. DOI: 10.1002/14651858.CD005317. pub2.
70. Attard A, Ranjith G, Taylor D. Delirium and its treatment. CNS Drugs 2008;22:631-644.
71. Bourne RS, Tahir TA, Borthwick M et al. Drug treatment of delirium: Past, present and future. J Psychosom Res 2008;65:273-282.
72. Twycross R, Wilcock A, eds. Hospice and Palliative Care Formulary USA. Nottingham: Palliativedrugs.com, 2006:103-104.
73. Boettger S, Breitbart W. Atypical antipsychotics in the management of delirium: A review of the empirical literature. Palliat Support Care 2005;3:227-237.
74. Gagnon B, Low G, Schreier G. Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: A prospective clinical study. J Psychiatry Neurosci 2005;30:100-107.
75. Breitbart W, Alici Y. Agitation and delirium at the end of life: "We couldn't manage him." JAMA 2008;300:2898-2910.
76. Hanania M, Kitain E. Melatonin for treatment and prevention of postoperative delirium. Anesth Analg 2002;94:338-339.
77. Nakamura K, Kurasawa M, Tanaka Y. Apomorphine-induced hypoattention in rats and reversal of the choice performance impairment by aniracetam. Eur J Pharmacol 1998;342:127-138.
78. Bourgeois JA, Koike AK, Simmons JE et al. Adjunctive valproic acid for delirium and/or agitation on a consultation-liaison service: A report of six cases. J Neuropsychiatry Clin Neurosci 2005;17:232-238.
79. Riker RR, Shehabi Y, Bokesch PM et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: A randomized trial. JAMA 2009;301:489-499.
80. Bayindir O, Güden M, Akpinar B et al. Ondansetron hydrochloride for the treatment of delirium after coronary artery surgery. J Thorac Cardiovasc Surg 2001;121:176-177.
81. Lacasse H, Perreault MM, Williamson DR. Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. Ann Pharmacother 2006;40:1966-1973.
82. Jackson KC, Lipman AG. Drug therapy for delirium in terminally ill patients. Cochrane Database Syst Rev 2004;(2):CD004770. DOI: 10.1002/14651858.CD004770.
83. Lonergan E, Britton AM, Luxenberg J. Antipsychotics for delirium. Cochrane Database Syst Rev 2007;(2):CD005594. DOI: 10.1002/14651858.CD005594. pub2.
84. Vella-Brincat J, Macleod AD. Haloperidol in palliative care. Palliat Med 2004;18:195-201.
85. Hassin-Baer S, Sirota P, Korczyn AD et al. Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm 2001;108:1299-1308.
86. American Psychiatric Association (APA). Practice guideline for the treatment of patients with delirium. Am J Psychiatry 1999;156(suppl 5):1-20.
87. Casarett DJ, Inouye SK. Diagnosis and management of delirium near the end of life. Ann Intern Med 2001;135:32-40.
88. Akechi T, Uchitomi Y, Okamura H et al. Usage of haloperidol for delirium in cancer patients. Support Care Cancer 1996;4:390-392.
89. Olofsson SM, Weitzner MA, Valentine AD et al. A retrospective study of the psychiatric management and outcome of delirium in the cancer patient. Support Care Cancer 1996;4:351-357.
90. Platt MM, Breitbart W, Smith M et al. Efficacy of neuroleptics for hypoactive delirium. J Neuropsychiatry Clin Neurosci 1994;6:66-67.
91. Horikawa N, Yamazaki T, Miyamoto K et al. Treatment for delirium with risperidone: Results of a prospective open trial with 10 patients. Gen Hosp Psychiatry 2003;25:289-292.
92. Shinno H, Matsuoka T, Yamamoto O et al. Successful treatment with quetiapine for delirium in terminally ill cancer patients. Psychogeriatrics 2007;7:64-68.
93. Straker DA, Shapiro PA, Muskin PR. Aripiprazole in the treatment of delirium. Psychosomatics 2006;47:385-391.
94. Jayaram MB, Hosalli P, Stroup S. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev 2006;(2):CD005237. DOI: 10.1002/14651858.CD005237.pub2.
95. Delgado-Guay M, Curry E, Bruera E et al. Subcutaneous olanzapine for hyperactive or mixed delirium in a comprehensive cancer center [abstract 191]. Palliat Med 2008;22:457.
96. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14:191-210.
97. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebocontrolled trials. JAMA 2005;294:1934-1943.
98. Wang PS, Schneeweiss S, Avorn J et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353:2335-2341.
99. U.S. Food and Drug Administration. Deaths With Antipsychotics in Elderly Patients With Behavioral Disturbances. Silver Spring, MD: U.S. Food and Drug Administration, 2005. Available at http://www.fda.gov/Drugs/DrugSafety/ PublicHealthAdvisories/ucm053171.htm, accessed September 2, 2009.
100. U.S. Food and Drug Administration. Conventional Antipsychotics - Healthcare Professional Sheet Text Version. Silver Spring, MD: U.S. Food and Drug Administration, 2008. Available at http://www.fda.gov/Drugs/ ResourcesForYou/HealthProfessionals/ucm124830.htm, accessed September 2, 2009.
101. Ray WA, Chung CP, Murray KT et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-235.
102. U.S. Food and Drug Administration. Haloperidol (Marketed as Haldol, Haldol Decanoate and Haldol Lactate). Silver Spring, MD: U.S. Food and Drug Administration, 2007. Available at http://www.fda.gov/Drugs/ResourcesForYou/ HealthProfessionals/ucm085203.htm, accessed September 2, 2009.
103. Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: Case reports and a review of the literature. Psychosomatics 2009;50:8-15.
104. Zimberg M, Berenson S. Delirium in patients with cancer: Nursing assessment and intervention. Oncol Nurs Forum 1990;17:529-538.
105. Gagnon P, Charbonneau C, Allard P et al. Delirium in advanced cancer: A psychoeducational intervention for family caregivers. J Palliat Care 2002;18:253-261.
106. Spiegel D. Essentials of psychotherapeutic intervention for cancer patients. Support Care Cancer 1995;3:252-256.
107. Elsayem A, Curry Iii E, Boohene J et al. Use of palliative sedation for intractable symptoms in the palliative care unit of a comprehensive cancer center. Support Care Cancer 2009;17:53-59.
108. de Graeff A, Dean M. Palliative sedation therapy in the last weeks of life: A literature review and recommendations for standards. J Palliat Med 2007;10:67-85.
109. Chater S, Viola R, Paterson J et al. Sedation for intractable distress in the dying - a survey of experts. Palliat Med 1998;12:255-269.
110. Burke AL, Diamond PL, Hulbert J et al. Terminal restlessness - its management and the role of midazolam. Med J Aust 1991;155:485-487.
111. Stirling LC, Kurowska A, Tookman A. The use of phenobarbitone in the management of agitation and seizures at the end of life. J Pain Symptom Manage 1999;17:363-368.
112. Lundström S, Zachrisson U, Fürst CJ. When nothing helps: Propofol as sedative and antiemetic in palliative cancer care. J Pain Symptom Manage 2005;30:570-577.
113. Maltoni M, Caraceni A, Brunelli C et al. Prognostic factors in advanced cancer patients: Evidence-based clinical recommendations - a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005;23:6240-6248.
114. Leonard M, Raju B, Conroy M et al. Reversibility of delirium in terminally ill patients and predictors of mortality. Palliat Med 2008;22:848-854.
115. Cole MG, Ciampi A, Belzile E et al. Persistent delirium in older hospital patients: A systematic review of frequency and prognosis. Age Ageing 2009;38:19-26.